BRIEF published on 05/14/2024 at 22:26, 1 year 7 months ago Bausch Health Announces Updates on Norwich XIFAXAN Litigation and New FDA Submission XIFAXAN Bausch Health Patent Litigation FDA Submission Norwich Pharmaceuticals
BRIEF published on 05/14/2024 at 22:26, 1 year 7 months ago Bausch Health annonce des mises à jour sur le litige Norwich XIFAXAN et une nouvelle soumission à la FDA XIFAXAN Bausch Santé Contentieux Des Brevets Norwich Pharmaceutique Soumission À La FDA
BRIEF published on 05/14/2024 at 22:20, 1 year 7 months ago Sonnet BioTherapeutics Announces Fiscal Year 2024 Q2 Results and Business Updates Financial Results Clinical Trials Oncology Biopharmaceuticals Sonnet BioTherapeutics
BRIEF published on 05/14/2024 at 22:20, 1 year 7 months ago Sonnet BioTherapeutics annonce ses résultats du deuxième trimestre de l'exercice 2024 et des mises à jour sur ses activités Résultats Financiers Essais Cliniques Oncologie Sonnet BioTherapeutics Produits Biopharmaceutiques
BRIEF published on 05/14/2024 at 22:20, 1 year 7 months ago NANOBIOTIX Lance une Étude de Phase 2 sur le Traitement du Cancer du Poumon avec FDA Approval FDA Étude De Phase 2 NANOBIOTIX Cancer Du Poumon NBTXR3
BRIEF published on 05/14/2024 at 22:20, 1 year 7 months ago NANOBIOTIX Launches Phase 2 Lung Cancer Treatment Study with FDA Approval FDA Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer
BRIEF published on 05/14/2024 at 22:15, 1 year 7 months ago GENFIT Announces Q1 2024 Financials and Projects Cash Runway into Late 2025 Cash Position Clinical Trials Revenue Decline Biopharmaceutical Industry GENFIT Financial Results
BRIEF published on 05/14/2024 at 22:15, 1 year 7 months ago GENFIT annonce ses résultats financiers du premier trimestre 2024 et dispose d'une trésorerie disponible jusqu'à fin 2025 Industrie Biopharmaceutique Essais Cliniques Baisse Des Revenus Résultats Financiers De GENFIT Situation De Trésorerie
BRIEF published on 05/14/2024 at 22:10, 1 year 7 months ago Protagonist Therapeutics to Present New Rusfertide Study Data at EHA Congress 2024 Clinical Study Protagonist Therapeutics Rusfertide Polycythemia Vera EHA Congress 2024
BRIEF published on 05/14/2024 at 22:10, 1 year 7 months ago Protagonist Therapeutics présentera de nouvelles données de l'étude Rusfertide au congrès de l'EHA 2024 Étude Clinique Rusfertide Thérapeutique Protagoniste Polyglobulie Vraie Congrès EHA 2024
Published on 01/14/2026 at 15:00, 10 minutes ago Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts
Published on 01/14/2026 at 14:30, 40 minutes ago Zimtu Capital Corp. Enters into Option Agreement to Acquire Interest in the Monument Peak Copper-Silver Project, Idaho
Published on 01/14/2026 at 14:00, 1 hour 10 minutes ago BTU 2025 Highlights and Drilling Plans for Three Projects in 2026
Published on 01/14/2026 at 13:30, 1 hour 40 minutes ago Nextech3D.ai's KraftyLab Accelerates Global Scale with Launch of In-Person Experiences and AI-Driven Platform Automation
Published on 01/14/2026 at 13:23, 1 hour 47 minutes ago SLAM Cuts High Grade Gold & Silver in Channel Samples
Published on 01/14/2026 at 14:30, 40 minutes ago Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc
Published on 01/14/2026 at 14:15, 55 minutes ago Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
Published on 01/14/2026 at 14:05, 1 hour 5 minutes ago Strong Q3 Performance: Sequential Revenue Growth of 0.6% in CC, Large Deal Wins of $4.8 billion
Published on 01/14/2026 at 10:26, 4 hours 44 minutes ago Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Published on 01/14/2026 at 08:45, 6 hours 25 minutes ago Arnaud Lagardère appointed Non-Executive Chairman of Lagardère Travel Retail. Frédéric Chevalier succeeds Dag Rasmussen from March 1st 2026
Published on 01/14/2026 at 08:45, 6 hours 25 minutes ago Arnaud Lagardère appointed Non-Executive Chairman of Lagardère Travel Retail. Frédéric Chevalier succeeds Dag Rasmussen from March 1st, 2026
Published on 01/14/2026 at 08:45, 6 hours 25 minutes ago Arnaud Lagardère est nommé Président non exécutif de Lagardère Travel Retail. Frédéric Chevalier succède à Dag Rasmussen à compter du 1er mars 2026.
Published on 01/13/2026 at 18:27, 20 hours 42 minutes ago 260113 BENETEAU Déclaration du nombre d'actions et de droits de vote au 31-12-2025
